Fig. 3From: Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infectionsCost-effectiveness plane. X-axis: Incremental QALYs, Y-axis: Incremental costs (USD), QALY: Quality-adjusted life yearBack to article page